Merck & Co. stock costs EUR 130.64 at USD 359.9 billion market cap
Published on 10/12/2026 at 16:00 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSKey points in brief
- Merck & Co. stock was at EUR 130.64 at Lang & Schwarz on October 12, 2026, plus 0.97 percent versus the October 9 Xetra close.
- The company had a USD 359.9 billion market capitalization and a 52-week USD 82.01 to USD 156.92 range.
- Cantor Fitzgerald raised its Merck target from USD 120.00 to USD 145.00 on October 8, 2026, while keeping a Neutral rating.
- Merck scheduled its third-quarter 2026 sales and earnings conference call for October 29, 2026.
Merck & Co. (ISIN US58933Y1055) was trading at EUR 130.64 at Lang & Schwarz on October 12, 2026 at 3:45 p.m. CEST, plus 0.97 percent versus the Xetra close of October 9, 2026 at EUR 129.38. Market capitalization stood at USD 359.9 billion on October 12, 2026.
Price stays below yearly high
The US primary listing was last at USD 145.73 on the NYSE on October 12, 2026 at 9:59 a.m. ET. Merck & Co. stock remained within a USD 82.01 to USD 156.92 52-week range, placing the latest US quote 7.13 percent below the yearly high.
Trading volume was 832,305 shares against an average volume of 9,806,603 shares on October 12, 2026. The gap between current volume and the average gives the session a lighter turnover profile, while the price remains 11.41 percent above the 52-week midpoint of USD 119.47.
Valuation and analyst target
Merck's price-earnings ratio was 116.56 on October 12, 2026. The elevated ratio reflects the earnings base used by the quote data and makes the upcoming reporting date more important for interpreting the stock's valuation.
According to Markets Insider on October 8, 2026, Cantor Fitzgerald analyst Carter Gould raised the target from USD 120.00 to USD 145.00 and kept a Neutral rating. The new target lies 0.52 percent below the latest USD 145.73 NYSE quote.
Comparison with peers
- Merck & Co. (NYSE, USD): plus 0.97 percent, P/E 116.56, market capitalization USD 359.9 billion
- Bristol-Myers Squibb (NYSE, USD): minus 2.32 percent, P/E 12.78, market capitalization USD 118.0 billion
- Pfizer (NYSE, USD): plus 0.30 percent, P/E 37.46, market capitalization USD 161.7 billion
October reporting date ahead
Merck & Co. scheduled its third-quarter 2026 sales and earnings conference call for October 29, 2026, at 9:00 a.m. ET. The date gives the market a defined point for testing the current valuation and the assumptions behind the raised Cantor target.
Market level and next signal
Merck & Co. was trading at EUR 130.64 at Lang & Schwarz on October 12, 2026 at 3:45 p.m. CEST, plus 0.97 percent versus the October 9, 2026 Xetra close of EUR 129.38. The bid was EUR 130.54 and the ask was EUR 130.74.
The further course of trading is shown by the continuously updated real-time quote of Merck & Co. stock.
Merck & Co. stock facts
- Company: Merck & Co., Inc.
- ISIN: US58933Y1055
- Ticker: MRK
- Primary exchange: NYSE
- Price Lang & Schwarz (as of October 12, 2026, 3:45 p.m. CEST): EUR 130.64
- Change versus October 9, 2026 close: plus 0.97 percent
- Market capitalization: USD 359.9 billion (as of October 12, 2026)
- 52-week range: USD 82.01-USD 156.92 (as of October 12, 2026)
- Sector / Industry: Healthcare / Drug Manufacturers - General
- Next earnings date: October 29, 2026
Market context: Market report S&P 500.
